Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Therapeutic resistance is a frequent problem of cancer treatment and a leading cause of mortality in patients with metastatic colorectal cancer (CRC). Recent insight into the mechanisms that confer multidrug resistance has elucidated that the ATP-binding cassette (ABC) superfamily G member 2 (ABCG2) assists cancer cells in escaping therapeutic stress caused by toxic chemotherapy. Therefore, it is necessary to develop ABCG2 inhibitors. In the present study, we investigated the inhibitory effect of KU55933 on ABCG2 in CRC. The cytotoxicity assay and drug accumulation assay were used to examine the inhibitory effect of KU55933 on ABCG2. The protein expressions were detected by Western blot assay. The docking assay was performed to predict the binding site and intermolecular interactions between KU55933 and ABCG2. KU55933 was more potent than the known ABCG2 inhibitor fumitremorgin C to enhance the sensitivity of mitoxantrone and doxorubicin and the intracellular accumulation of mitoxantrone, doxorubicin and rhodamine 123 inside CRC cells with ABCG2 overexpression. Moreover, KU55933 did not affect the protein level of ABCG2. Furthermore, the docking data showed that KU55933 was tightly located in the drug-binding pocket of ABCG2. In summary, our data presented that KU55933 could effectively inhibit the drug pump activity of ABCG2 in colorectal cancer, which is further supported by the predicted model that showed the hydrophobic interactions of KU55933 within the drug-binding pocket of ABCG2. KU55933 can potently inhibit the activity of ABCG2 in CRC. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Citation

Kun Liu, Yu Chen, Xiao-Bao Shi, Zi-Hao Xing, Zheng-Jie He, Sheng-Te Wang, Yan-Chi Li, Wei-Jing Liu, Peng-Wei Zhang, Ze-Zhong Yu, Xue-Mei Mo, Xing-Yuan Shi, Zhe-Sheng Chen, Zhi Shi. Inhibiting the Activity of ABCG2 by KU55933 in Colorectal Cancer. Recent patents on anti-cancer drug discovery. 2022;17(4):387-395

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 35023460

View Full Text